Metro Infectious Disease Consultants, LLC

Metro Infectious Disease Consultants, LLC was paid $44.34M by Medicaid between Jan 2018 and Dec 2024, across 35 billing codes. Its largest line is J3380, Injection, vedolizumab, intravenous, 1 mg — 23% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	27,702	$2.48M
2019	26,400	$4.32M
2020	31,207	$5.23M
2021	34,254	$7.94M
2022	33,157	$9.18M
2023	31,508	$9.41M
2024incomplete	23,667	$5.79M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J3380	Injection, vedolizumab, intravenous, 1 mg	23%	2,137	2,034	$10.25M
J2350	Injection, ocrelizumab, 1 mg	20%	365	336	$8.65M
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	11%	4,484	2,608	$4.92M
99233	Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m	10%	90,873	31,204	$4.56M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	8.9%	3,174	1,742	$3.93M
J2323	Injection, natalizumab, 1 mg	6.2%	564	530	$2.74M
J2357	Injection, omalizumab, 5 mg	5.3%	1,534	1,110	$2.34M
J2182	Injection, mepolizumab, 1 mg	3.2%	641	597	$1.41M
99232	Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity	2.7%	33,420	14,748	$1.21M
99223	Prolong inpt eval add15 m	1.9%	8,929	8,568	$847K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	1.6%	726	425	$728K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	1.2%	8,871	7,967	$553K

23 more codes

99255		1.2%	4,930	$532K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	1.1%	18,698	$482K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	<1%	135	$425K
99222	Initial hospital care, per day, moderate complexity	<1%	2,485	$175K
99214	Doctor's office visit, returning patient (more involved)	<1%	2,312	$141K
96415		<1%	6,557	$105K
99254		<1%	1,183	$100K
99213	Doctor's office visit, returning patient (routine)	<1%	1,067	$43K
J1335	Injection, ertapenem sodium, 500 mg	<1%	1,370	$41K
99215	Doctor's office visit, returning patient (complex)	<1%	372	$32K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	2,832	$30K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	1,353	$30K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	1,411	$21K
96375	Therapeutic injection; each additional sequential IV push	<1%	2,395	$18K
96401		<1%	704	$18K
J0878	Injection, daptomycin, 1 mg	<1%	278	$14K
36415	Collection of venous blood by venipuncture	<1%	2,308	$6K
99204	Doctor's office visit, new patient (more involved)	<1%	70	$6K
99231	Subsequent hospital care, per day, straightforward or low complexity	<1%	172	$4K
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	<1%	67	$817.03
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	1,236	$716.21
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	<1%	149	$586.96
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	93	$538.47

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPETRAK, RUSSELL (MANAGING PARTNER)